Can machine learning predict endometrial cancer in patients with postmenopausal uterine bleeding?
Department of Obstetrics and Gynaecology, Meir Medical Center, Kfar Saba, Israel
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Menopause Rev 2026; 25(1): 1-6
Data publikacji online: 2026/05/27
Article file
- Moodley M, Roberts C. Clinical pathway for the evaluation of postmenopausal bleeding with an emphasis on endometrial cancer detection. J Obstet Gynaecol 2004; 24: 736-741. Smith PP, O’Connor S, Gupta J, Clark TJ. Recurrent postmenopausal bleeding: a prospective cohort study. J Minim Invasive Gynecol 2014; 21: 799-803. Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet 2022; 399: 1412-1428. Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer 2019; 145: 1719-1730. Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: a systematic review and meta-analysis. JAMA Intern Med 2018; 178: 1210-1222. Giannella L, Mfuta K, Setti T, Cerami LB, Bergamini E, Boselli F. A risk-scoring model for the prediction of endometrial cancer among symptomatic postmenopausal women with endometrial thickness > 4 mm. Biomed Res Int 2014; 2014: 130569. Munro MG. Investigation of women with postmenopausal uterine bleeding: clinical practice recommendations. Perm J 2014; 18: 55-70. Burbos N, Musonda P, Giarenis I, Shiner AM, Giamougiannis P, Morris EP, et al. Predicting the risk of endometrial cancer in postmenopausal women presenting with vaginal bleeding: the Norwich DEFAB risk assessment tool. Br J Cancer 2010; 102: 1201-1206. Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer. Oncol Lett 2015; 9: 1495-1501. Emons G, Mustea A, Tempfer C. Tamoxifen and endometrial cancer: a janus-headed drug. Cancers (Basel) 2020; 12: 1-15. Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas 2016; 91: 25-35. Hamet P. Cancer and hypertension: a potential for crosstalk? J Hypertens 1997; 15: 1573-1577. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension 1999; 34: 320-325. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 921-929. Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, et al. Evidence of a causal association between insulinemia and endometrial cancer: a mendelian randomization analysis. J Natl Cancer Inst 2015; 107: 1-7. Seckin B, Cicek MN, Dikmen AU, Bostancı EI, Muftuoglu KH. Diagnostic value of sonography for detecting endometrial pathologies in postmenopausal women with and without bleeding. J Clin Ultrasound 2016; 44: 339-346.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
